



# 128th MAINE LEGISLATURE

LD 114

LR 409(01)

## An Act To Increase the Number of Suboxone Prescribers

### Preliminary Fiscal Impact Statement for Original Bill

Sponsor: Rep. Madigan of Waterville

Committee: Labor, Commerce, Research and Economic Development

Fiscal Note Required: Yes

### Preliminary Fiscal Impact Statement

	FY 2017-18	FY 2018-19	Projections FY 2019-20	Projections FY 2020-21
<b>Net Cost (Savings)</b>				
General Fund	\$3,617,096	\$7,165,202	\$7,165,202	\$7,165,202
<b>Appropriations/Allocations</b>				
General Fund	\$3,617,096	\$7,165,202	\$7,165,202	\$7,165,202
Federal Expenditures Fund	(\$489,927)	(\$1,186,827)	(\$1,186,827)	(\$1,186,827)

#### Fiscal Detail and Notes

The Department of Health and Human Services will require General Fund appropriations of \$3,617,096 in fiscal year 2017-18 and \$7,165,202 in fiscal year 2018-19 to increase reimbursement rates under the MaineCare program for buprenorphine-medication-assisted treatment including prescriptions and accompanying services by 30% no later than January 1, 2018. Federal Expenditures Fund allocations will also be required for the FMAP match for portions of these changes.

However, effective 4/1/2017, the federal Centers for Medicare and Medicaid Services is establishing new federal upper payments for prescribed drugs-NADAC (National Average Drug Acquisition Cost), in which buprenorphine is included. This increase to the buprenorphine prescriptions will go above this new upper payment limit and any amount above this limit will be 100% state funded. So the overall impact of this change on the federal allocations will be a decrease.

Additional costs to the Board of Osteopathic Licensure and the Board of Licensure in Medicine, both of which are affiliated with the Department of Professional and Financial Regulation, to implement the requirements of this legislation can be absorbed within each board's existing budgeted resources.